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Abstract 
To compare clinical curative effects and toxicity of recombinant human adenovirus‑p53 injection (rAd‑p53, Gendicine) 
combining chemoradiotherapy (CRT)/radiotherapy (RT) with those obtained with CRT/RT alone in nasopharyngeal 
carcinoma (NPC). We searched all the eligible studies from the Pubmed, Cochran Library, Embase, Web of science, 
Wanfang database and Chinese National Knowledge Infrastructure (CNKI). A total of twelve studies including 566 
participants met the criteria to perform a meta‑analysis. The results indicated the complete remission (CR) and overall 
response (OR) in the combination therapy group were significantly improved compared with the CRT/RT group 
(CR:RR = 2.03, 95% CI 1.66–2.48, p < 0.00001; OR:RR = 1.23, 95% CI 1.13–1.33, p < 0.00001), and patients who received 
the combination therapy showed significantly prolonged 1‑ and 2‑year overall survival (OS), 2 year disease‑free sur‑
vival (DFS) rate and 2 year recurrence‑free survival (RFS) rate (1 year OS:RR = 1.08, 95% CI 1.00–1.17, p = 0.04; 2 year 
OS:RR = 1.12, 95% CI 1.00–1.26, p = 0.04; 2 year DFS:RR = 1.41, 95% CI 1.09–1.83, p = 0.008; 2 year RFS:RR = 1.16, 
95% CI 1.03–1.31, p = 0.02), but there was no significance in 3 year OS rate and 2 year distant metastases‑free survival 
(DMFS) rate (3 year OS:RR = 1.28, 95% CI 1.00–1.62, p = 0.05; 2 year DMFS:RR = 1.05, 95% CI 0.89–1.24, p = 0.55). Fur‑
thermore, CRT/RT combined with rAd‑p53 could not aggravate the myelosuppression versus CRT/RT alone (RR = 0.79, 
95% CI 0.51–1.23, p = 0.30). The results demonstrated CRT/RT combined with rAd‑p53 can result in enhanced survival 
and better clinical responses of patients with NPC. Therefore, rAd‑p53 has great potential as an effective therapy for 
NPC.
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Background
Nasopharyngeal carcinoma (NPC), arising from the 
nasopharynx epithelium, is a kind of head and neck can-
cers (Chua et  al. 2015). Worldwide, 86,500 cases were 
diagnosed with NPC in 2012, and the most of new cases 
were in China, Southeast Asia and other Asian countries. 
In recent years, Concurrent chemoradiotherapy (CRT) is 
being used in the treatment of NPC, gradually becoming 
the predominant method for the treatment of advanced 
NPC. However, the 5 year survival rate is only 40–50%.
As we know, the p53 tumor suppressor gene mutations 
or deletions are associated with malignant transforma-
tion and tumor progression (Lo et al. 2004; Golubovskaya 
et al. 2009; Olivier et al. 2002). The wildtype p53-induced 
phosphatase 1 (Wip1) protein was increased in advanced 
NPC, which may involve in the processes of prolifera-
tion, apoptosis, migration and invasion (Sun et al. 2015). 
Recombinant human adenovirus-p53 injection (rAd-p53, 
Gendicine) has been used for the clinical treatment of 
NPC. Despite the potential advantages of rAd-p53 for 
NPC, it is still not clear whether CRT/RT combined with 
rAd-p53 might be better than CRT/RT alone. Here, we 
performed a meta-analysis on twelve published clinical 
randomized controlled trials (RCTs) to derive a more 
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A systematic literature search was performed though 
Pubmed, Cochran Library, Embase, Web of science, Wan-
fang database, Chinese National Knowledge Infrastruc-
ture (CNKI), covering all articles published up to October 
2015. The search terms included “Recombinant human 
adenovirus-p53”, “rAd-p53”, “Gendicine”, “nasopharyn-
geal carcinoma” and “nasopharyngeal neoplasms”. The 
language was English or Chinese. When overlapping arti-
cles were found, we only included the publications that 
reported the most extensive information.
Selection criteria
This meta-analysis aimed to evaluate the impact of com-
bination therapy on patient survival, clinical responses 
and safety. So the selection criteria for this study were as 
follows: Firstly, trials were eligible for the present meta-
analysis if they were randomized controlled trials (RCTs) 
of patients with NPC. Secondly, the patients in the exper-
imental group received CRT/RT combined with rAd-p53, 
whereas patients in the control group were treated using 
CRT/RT alone. Thirdly, the endpoints were patient sur-
vival, clinical responses and safety.
Data extraction and quality assessment
The extraction of data was operated independently by two 
investigators (Cheng Yuan and Zhuo Chen). Disagreements 
were resolved through discussion with a third investiga-
tor (Xin-hua Xu). Then the following relevant information 
was extracted from the selected studies: the first author’s 
surname, year of publication, number of patients, tumor 
stages, CRT/RT regimens and dose of RAd-p53.
The quality was evaluated by the Jadad composite scale 
(Jadad et al. 1996). This scale included the method of ran-
domization (0–2 points), double blinding (0–2 points), 
and the description of dropouts (0–1 point).
Curative effect evaluation
Survival outcomes were assessed in terms of the overall 
survival (OS), disease-free survival (DFS), recurrence-
free survival (RFS) and distant metastases-free survival 
(DMFS) to evaluate prognosis, and treatment efficacy 
was assessed in terms of the overall response (OR) and 
complete response (CR). Toxicity event was assessed in 
terms of myelosuppression.
Statistical analysis
Results were reported as pooled as relative risk (RR) and 
their 95% confidence interval (CI). Firstly, heterogeneity 
was identified. If the heterogeneity was not significant 
(p  >  0.1, I2  <  50.0%), then the fixed-effect model can 
be performed, otherwise, the random effects model. 
Results of this meta-analysis were presented by forest 
plots, and the p value less than 0.05 was considered sig-
nificant. Publication bias was evaluated though funnel 
plots. All analyses were performed by Review Manager 
(version 5.3, the Cochrane collaboration), using two 
side p values.
Results
Search results and characteristics of studies
Our search strategy identified 115 potentially relevant 
studies, and a total of twelve literatures were adopted in 
the end. The characteristics of the twelve studies (Zhang 
et  al. 2006, 2007, 2011; Pan et  al. 2009; Lan et  al. 2011, 
2012; Qin et al. 2012; Wang et al. 2010, 2012; Li 2012; Si 
et al. 2009; Chen et al. 2003) were summarized in Table 1. 
A total of 566 patients were included in the meta-analysis, 
of whom 298 received CRT/RT combined with rAd-p53 
and 268 were treated with CRT/RT alone.
Recent efficacy assessments
Recent efficacy was assessed in terms of CR and OR. 
Twelve studies compared CR, of which 298 patients were 
treated with CRT/RT combined with rAd-p53 and 268 
patients were treated with CRT/RT alone, and ten trials 
including 464 patients compared OR. As shown in Figs. 1, 
2, the analysis results indicated that the CR and OR in the 
combination therapy group were significantly improved 
compared with the CRT/RT group (CR:RR =  2.03, 95% 
CI 1.66–2.48, p < 0.00001; OR:RR = 1.23, 95% CI 1.13–
1.33, p < 0.00001).
Survival outcome
There were four eligible studies that reported the end-
points of 1- and 2-year OS rate. CRT/RT combined with 
rAd-p53 showed significantly increased 1- and 2-year OS 
rates compared with the rates observed when CRT/RT 
alone was used (1-year OS:RR = 1.08, 95% CI 1.00–1.17, 
p = 0.04, Fig. 3a and 2-year OS:RR = 1.12, 95% CI 1.00–
1.26, p = 0.04, Fig. 3b). In addition, two studies compared 
3 year OS, and the result of meta-analysis showed there 
was no significance in the outcome of 3-year OS versus 
control (RR = 1.28, 95% CI 1.00–1.62, p = 0.05; Fig. 3c).
As shown in Fig. 4, patients who received the combina-
tion therapy showed significantly prolonged 2  year DFS 
rate and 2  year RFS rate compared with patients who 
received CRT/RT alone, but there was no significance in 
2 year DMFS rate (2 year DFS:RR = 1.41, 95% CI 1.09–
1.83, p =  0.008, Fig.  4a; 2-year RFS:RR =  1.16, 95% CI 
1.03–1.31, p = 0.02, Fig. 4b; 2-year DMFS:RR = 1.05, 95% 
CI 0.89–1.24, p = 0.55, Fig. 4c).
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Toxicity
Data available regarding the toxicities were limited. The 
reporting and occurrence of adverse events was rare. The 
most common side effect was fever which was reported, 
but it was not compared between the combination 
therapy group and CRT/RT group. Only 2 of the 12 trials 
reported the occurrence of myelosuppression. The result 
indicated CRT/RT combined with rAd-p53 could not 
aggravate the myelosuppression compared with CRT/RT 
alone (RR = 0.79, 95% CI 0.51–1.23, p = 0.30; Fig. 5).
Table 1 Main characteristics of all the included studies
RAd-p53 recombinant human adenovirus-p53 injection; RT radiotherapy; CT chemotherapy
Studies RAd-p53 RT CT Stages Jadad














Wang et al. (2010) 1 × 1012 VP




Li (2012) 1 × 1012 VP
–





Chen et al. (2003) 1 × 1012 VP
1 time/week/8 weeks
Nasopharynx: 70–76 Gy/7–8 weeks
Neck: 60–70 Gy/7–8 weeks
– II–IV 2
Si et al. (2009) 1 × 1012 VP
1 time/week/6–8 weeks
Nasopharynx: 70–76 Gy/7–8 weeks















Zhang et al. (2011) 2 × 1012 VP
1 time/week/6 weeks
68–76 Gy to 60–70 Gy/6 weeks Cisplatin: 75 mg/m2
Paclitaxel: 75 mg/m2
III–IV 3





Lan et al. (2012) 1 × 1012 VP
1 time/3 days/6–8 times
70–76 Gy/35–38f Cisplatin: 300 mg/m2
5‑Fluorouracil: 2000 mg/m2
Unclear 2
Zhang et al. (2007) 1 × 1012 VP




Fig. 1 Forest plot for the meta‑analysis of complete remission (CR) rate of primary tumor
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Fig. 2 Forest plot for the meta‑analysis of overall response (OR) rates of primary tumor
Fig. 3 Forest plot for the meta‑analysis of the 1‑, 2‑ and 3‑year overall survival (OS) rate
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Heterogeneity and publication bias
There was no evidence of heterogeneity in all the recent 
efficacy, survival outcomes and toxicity in the Chi square 
and I-square tests, and a fixed effect model was used. 
Funnel plot was performed to assess the publication 
bias in all the included studies for evaluation of the CR. 
Since no more than 10 studies were included in the OR, 
survival outcomes and toxicity, funnel plot was not per-
formed. As shown in Fig. 6, the funnel plot did not reveal 
any evidence of significant asymmetry in CR.
Discussion
To our knowledge, this is the first meta-analysis to 
explore the curative efficacy of rAd-p53 in the treat-
ment of NPC. During the past decades, despite progress 
in technique evolution of RT, the long-term survival rate 
of NPC did not receive fundamental improvement, so 
that developing new effective therapeutic modality are 
urgent need (Mitchell et al. 2010). In 2003, a gene therapy 
product (non-replicating adenovirus) received approval 
for the treatment of head and neck cancer, and then a 
Fig. 4 Forest plot for the meta‑analysis of the 2 year disease‑free survival (DFS) rate, recurrence‑free survival (RFS) rate and distant metastases‑free 
survival (DMFS) rate
Fig. 5 Forest plot for the meta‑analysis of the occurrence of myelosuppression
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replication-selective adenovirus was used to treat NPC 
(Hughes et al. 2012). Nevertheless, it is very necessary to 
have a systematic comparison for the curative effects and 
toxicity between CRT/RT combined with rAd-p53 and 
CRT/RT alone.
In our study, our meta-analysis including data from 
twelve published studies with 566 patients indicated that 
CR and OR in the combination therapy group were sig-
nificantly improved compared with the CRT/RT group. 
Combination therapy showed significantly prolonged 1- 
and 2-year OS rate, 2 year DFS rate and 2 year RFS rate. 
While, there was no significance in 3  year OS rate and 
2  year DMFS rate. In addition, CRT/RT combined with 
rAd-p53 could not aggravate the myelosuppression ver-
sus CRT/RT alone.
For this reason that adeno-associated virus (AAV) 
cannot replicate on its own, recombinant adeno-asso-
ciated viruses (rAAV) garnered much attention in the 
field of gene therapy to the cancer, which can overcome 
transduction barriers at the level of receptor binding, 
subcellular trafficking, and transgene expression (Mitch-
ell et  al. 2010; Nicolson and Samulski 2014). The wild-
type p53 gene (wt-p53) influences cell survival and the 
response to radiation-induced DNA damage. The stud-
ies (Hirao et  al. 2000; Ma et  al. 2012) found activated 
p53 transcription promotes can lead to cell cycle arrest, 
DNA repair, tumor cell apoptosis, and even killing effect 
on tumor cells. A previous study (Kandioler et al. 2002) 
suggested that patients were less sensitive to RT if the 
function of wt-p53 lost, and RT combined with rAd-
p53 may increase the sensitivity in  vivo and in  vitro 
studies (Shiomitsu et  al. 2008; Gudkov and Komarova 
2003; Cuddihy and Bristow 2004). RAd-p53 can carry 
the recombinant human p53 gene and then introduce 
the p53 gene into tumor cells to express wt-p53 protein, 
inhibiting cell division and inducing tumor cell apoptosis 
(Pan et al. 2009).
However, the limitations of the study cannot be 
ignored. Firstly, the twelve trials included in the meta-
analysis were mainly concentrated in the Chinese popu-
lation, and this may be related to the high incidence of 
NPC in China. Secondly, there was limited information 
regarding some patients, and the total sample sizes were 
small. Thirdly, literatures were searched by English and 
Chinese, which may lead to potential publication bias, 
although publication bias was not significant in the study.
In conclusion, our results demonstrated that CRT/RT 
combined with rAd-p53 therapy can result in enhanced 
survival and better clinical responses of patients with 
NPC. Therefore, rAd-p53 has great potential as an effec-
tive therapy for NPC.
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